Hims & Hers Health, Inc. $HIMS Shares Bought by Fiduciary Alliance LLC

Fiduciary Alliance LLC lifted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 24.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,022 shares of the company’s stock after acquiring an additional 26,769 shares during the quarter. Fiduciary Alliance LLC owned 0.06% of Hims & Hers Health worth $7,715,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of HIMS. Invesco Ltd. raised its holdings in Hims & Hers Health by 502.2% during the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock worth $127,237,000 after purchasing an additional 2,128,587 shares during the last quarter. Clear Street LLC acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth $83,582,000. Norges Bank purchased a new stake in shares of Hims & Hers Health in the 2nd quarter worth about $78,464,000. Marex Group plc acquired a new stake in Hims & Hers Health in the 2nd quarter valued at about $53,626,000. Finally, Man Group plc grew its stake in Hims & Hers Health by 345.9% in the 2nd quarter. Man Group plc now owns 816,582 shares of the company’s stock valued at $40,707,000 after acquiring an additional 633,432 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Canaccord Genuity Group restated a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a research report on Friday, September 12th. UBS Group set a $32.00 price objective on Hims & Hers Health in a research report on Tuesday, November 4th. BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Barclays began coverage on Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $45.50.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 85,000 shares of Hims & Hers Health stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $60.20, for a total value of $5,117,000.00. Following the completion of the sale, the chief financial officer owned 70,232 shares in the company, valued at $4,227,966.40. The trade was a 54.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $42.53, for a total transaction of $112,151.61. Following the transaction, the insider directly owned 155,856 shares of the company’s stock, valued at approximately $6,628,555.68. This represents a 1.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 194,193 shares of company stock worth $10,329,018 over the last quarter. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Down 5.1%

HIMS stock opened at $34.98 on Thursday. The stock has a market capitalization of $7.96 billion, a P/E ratio of 64.77, a PEG ratio of 7.29 and a beta of 2.41. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. Hims & Hers Health, Inc. has a one year low of $23.97 and a one year high of $72.98. The company has a 50 day moving average price of $42.69 and a two-hundred day moving average price of $48.78.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same period in the prior year, the company earned $0.32 EPS. The company’s revenue for the quarter was up 49.2% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health declared that its board has authorized a share buyback program on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 3% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.